CN116271117A - Cd8成像构建体及其使用方法 - Google Patents
Cd8成像构建体及其使用方法 Download PDFInfo
- Publication number
- CN116271117A CN116271117A CN202211648348.2A CN202211648348A CN116271117A CN 116271117 A CN116271117 A CN 116271117A CN 202211648348 A CN202211648348 A CN 202211648348A CN 116271117 A CN116271117 A CN 116271117A
- Authority
- CN
- China
- Prior art keywords
- subject
- tumor
- binding construct
- administering
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738938P | 2018-09-28 | 2018-09-28 | |
| US62/738,938 | 2018-09-28 | ||
| US201962826606P | 2019-03-29 | 2019-03-29 | |
| US62/826,606 | 2019-03-29 | ||
| CN201980079379.0A CN113166255A (zh) | 2018-09-28 | 2019-09-27 | Cd8成像构建体及其使用方法 |
| PCT/US2019/053642 WO2020069433A1 (en) | 2018-09-28 | 2019-09-27 | Cd8 imaging constructs and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980079379.0A Division CN113166255A (zh) | 2018-09-28 | 2019-09-27 | Cd8成像构建体及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116271117A true CN116271117A (zh) | 2023-06-23 |
Family
ID=69949940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211648348.2A Pending CN116271117A (zh) | 2018-09-28 | 2019-09-27 | Cd8成像构建体及其使用方法 |
| CN201980079379.0A Pending CN113166255A (zh) | 2018-09-28 | 2019-09-27 | Cd8成像构建体及其使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980079379.0A Pending CN113166255A (zh) | 2018-09-28 | 2019-09-27 | Cd8成像构建体及其使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220001043A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4205769A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022501402A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210087938A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116271117A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019351264B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3113080A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020069433A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd8에의 항원 결합 구조체들 |
| EP3964507A1 (en) | 2013-10-04 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| AU2019282248A1 (en) | 2018-06-08 | 2021-01-07 | Imaginab, Inc. | Antigen binding constructs to CD4 |
| GB2584086A (en) * | 2019-05-17 | 2020-11-25 | Univ Oxford Innovation Ltd | A method for identity validation and quality assurance of quantitative magnetic resonance imaging protocols |
| JP7810446B2 (ja) * | 2020-09-17 | 2026-02-03 | サニーベイ・バイオテック・インコーポレイテッド | Herv-k抗体治療薬 |
| KR20230151513A (ko) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Cd8 표적 바이러스 벡터의 용도 |
| AU2022388729A1 (en) | 2021-11-10 | 2024-05-16 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN115927342B (zh) * | 2022-07-08 | 2025-09-23 | 新疆医科大学 | 特异识别CD8α分子的高亲和力核酸适配体 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| EP4590688A1 (en) | 2022-09-21 | 2025-07-30 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| CN120380327A (zh) | 2022-12-26 | 2025-07-25 | 富士胶片株式会社 | 荧光强度增强剂、经荧光标记的靶标生物物质的荧光强度增强方法及荧光检测用试剂盒 |
| CN116130131B (zh) * | 2022-12-30 | 2026-02-06 | 中国核动力研究设计院 | 一种一回路压力边界泄漏辐射监测装置及其监测方法 |
| JP2026502532A (ja) * | 2023-01-12 | 2026-01-23 | ナショナル ユニバーシティ オブ シンガポール | T細胞及びnk細胞悪性腫瘍の免疫療法のためのcd8発現及びキメラ抗原受容体の遮断 |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025064435A1 (en) | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| US12086990B1 (en) * | 2024-04-23 | 2024-09-10 | MultiFunctional Imaging LLC | Systems and methods for simultaneous imaging of multiple positron emission tomography (PET) tracers |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271462A1 (en) * | 2013-03-13 | 2014-09-18 | Imaginab, Inc. | Antigen binding constructs to cd8 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
| US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
| US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| JP2008539220A (ja) * | 2005-04-26 | 2008-11-13 | ファイザー・リミテッド | バソプレシンアンタゴニストとしてのトリアゾール誘導体 |
| US8557257B2 (en) * | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP4877766B2 (ja) | 2006-08-25 | 2012-02-15 | 独立行政法人放射線医学総合研究所 | 陽電子放射断層撮像装置及び放射線検出器 |
| US20130137975A1 (en) * | 2010-02-09 | 2013-05-30 | OSI Pharmaceuticals, LLC | Pet imaging |
| AU2012212006A1 (en) | 2011-02-03 | 2013-08-15 | California Institute Of Technology | PSA capture agents, compositions, methods and preparation thereof |
| US8993971B2 (en) | 2011-06-15 | 2015-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | High resolution positron emission tomography |
| US9239332B2 (en) | 2011-07-11 | 2016-01-19 | Indi Molecular, Inc. | Akt-specific capture agents, compositions, and methods of using and making |
| US8710180B2 (en) | 2011-08-31 | 2014-04-29 | Indi Molecular, Inc. | VEGF-specific capture agents, compositions, and methods of using and making |
| CA2865774A1 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Psma as a biomarker for androgen activity in prostate cancer |
| US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014074907A1 (en) | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| CN105979872A (zh) | 2013-09-25 | 2016-09-28 | 理查德·R·布莱克 | 正电子发射断层摄影数据的病人特异性分析 |
| DE102014200303B4 (de) | 2014-01-10 | 2015-10-29 | Siemens Aktiengesellschaft | Verfahren zur Durchführung einer Positronenemissionstomographie in einer Hybridanlage und entsprechende Hybridanlage |
| EA201792442A1 (ru) * | 2015-05-06 | 2018-06-29 | Янссен Байотек, Инк. | Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение |
| CN108136012B (zh) * | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| CN105395209B (zh) | 2015-12-01 | 2018-10-02 | 沈阳东软医疗系统有限公司 | 一种正电子发射断层扫描成像系统及方法 |
| WO2017176769A1 (en) | 2016-04-04 | 2017-10-12 | Indi Molecular, Inc. | Cd8-specific capture agents, compositions, and methods of using and making |
| CN109414238B (zh) | 2016-06-12 | 2023-01-03 | 上海联影医疗科技股份有限公司 | 正电子发射断层成像系统及其图像重建方法 |
| WO2019033043A2 (en) * | 2017-08-11 | 2019-02-14 | Genentech, Inc. | ANTI-CD8 ANTIBODIES AND USES THEREOF |
-
2019
- 2019-09-27 WO PCT/US2019/053642 patent/WO2020069433A1/en not_active Ceased
- 2019-09-27 CA CA3113080A patent/CA3113080A1/en active Pending
- 2019-09-27 CN CN202211648348.2A patent/CN116271117A/zh active Pending
- 2019-09-27 EP EP22182384.2A patent/EP4205769A1/en active Pending
- 2019-09-27 US US17/280,137 patent/US20220001043A1/en active Pending
- 2019-09-27 EP EP19866804.8A patent/EP3856786A4/en active Pending
- 2019-09-27 KR KR1020217012365A patent/KR20210087938A/ko active Pending
- 2019-09-27 CN CN201980079379.0A patent/CN113166255A/zh active Pending
- 2019-09-27 JP JP2021517437A patent/JP2022501402A/ja active Pending
- 2019-09-27 AU AU2019351264A patent/AU2019351264B2/en active Active
-
2024
- 2024-12-13 JP JP2024218898A patent/JP2025060696A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140271462A1 (en) * | 2013-03-13 | 2014-09-18 | Imaginab, Inc. | Antigen binding constructs to cd8 |
Non-Patent Citations (3)
| Title |
|---|
| IMAGINAB, INC.: "89Zr-Df-IAB22M2C PET/ CT in Patients With Selected Solid Malignancies or Hodgkin\'s Lymphoma", NATIONAL LIBRARY OF MEDICINE, 18 September 2018 (2018-09-18), pages 1 - 11 * |
| NEETA PANDIT-TASKAR等: "First in Human Phase I Imaging Study With 89Zr-IAB22M2C Anti CD8 Minibody in Patients with SolidTumors", JOURNAL OF NUCLEAR MEDICINE, 31 May 2018 (2018-05-31), pages 1 - 4 * |
| YVONNEW.S.JAUW等: "Immuno-PositronEmissionTomographywithZirconium-89-LabeledMonoclonalAntibodiesinOncology:WhatCanWeLearnfromInitialClinicalTrials?", FRONTIERSINPHARMACOLOGY, vol. 7, 24 May 2016 (2016-05-24), pages 1 - 15 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220001043A1 (en) | 2022-01-06 |
| WO2020069433A1 (en) | 2020-04-02 |
| JP2022501402A (ja) | 2022-01-06 |
| CA3113080A1 (en) | 2020-04-02 |
| EP3856786A1 (en) | 2021-08-04 |
| EP4205769A9 (en) | 2023-08-23 |
| AU2019351264A1 (en) | 2021-04-29 |
| KR20210087938A (ko) | 2021-07-13 |
| JP2025060696A (ja) | 2025-04-10 |
| EP4205769A1 (en) | 2023-07-05 |
| EP3856786A4 (en) | 2022-07-20 |
| AU2019351264B2 (en) | 2026-07-02 |
| CN113166255A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4205769A9 (en) | Cd8 imaging constructs and methods of use thereof | |
| Tagawa et al. | Phase II study of lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer | |
| CN101824090B (zh) | 人源化单克隆抗体hPAM4 | |
| US11427648B2 (en) | Anti-CD146 antibodies and uses thereof | |
| Hong et al. | Positron emission tomography imaging of CD105 expression during tumor angiogenesis | |
| JP5906090B2 (ja) | 癌の診断のための方法およびキットならびに治療価の推定 | |
| Liu et al. | 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model | |
| US20230211024A1 (en) | Methods of imaging using multiple imaging agents | |
| CN114616250A (zh) | Cd8结合剂及其用途 | |
| WO2019033043A2 (en) | ANTI-CD8 ANTIBODIES AND USES THEREOF | |
| JP2006507803A (ja) | モノクローナル抗体pam4ならびに膵臓癌の診断および治療のためのその使用 | |
| AU2016268038A1 (en) | Systems and methods for determining optimum patient-specific antibody dose for tumor targeting | |
| Burvenich et al. | Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa | |
| Achmad et al. | Predicting cetuximab accumulation in KRAS wild‐type and KRAS mutant colorectal cancer using 64Cu‐labeled cetuximab positron emission tomography | |
| Shooli et al. | Theranostics in brain tumors | |
| Ku et al. | MicroSPECT/CT imaging of cell-line and patient-derived EGFR-positive tumor xenografts in mice with panitumumab fab modified with hexahistidine peptides to enable labeling with 99mTc (I) tricarbonyl complex | |
| Martiniova et al. | The role of radiolabeled monoclonal antibodies in cancer imaging and ADC treatment | |
| WO2024041574A1 (en) | Non-invasive methods using anti-cldn18.2 antibody-radionuclide conjugates | |
| Ghosh et al. | Clinical development of an anti-GPC-1 antibody for the treatment of cancer | |
| Ychou et al. | Adjuvant Radioimmunotherapy Trial with Iodine-131–Labeled Anti–Carcinoembryonic Antigen Monoclonal Antibody F6 F (ab′) 2 after Resection of Liver Metastases from Colorectal Cancer | |
| JP2017214308A (ja) | 放射性医薬組成物、及び、放射能標識抗体のスクリーニング方法 | |
| HK40059336A (en) | Cd8 imaging constructs and methods of use thereof | |
| Kwon | Positron Emission Tomography (PET) of Breast cancer heterogeneous for HER2 and EGFR using bispecific radioimmunoconjugates | |
| Ku | Theranostic Implications of Molecular Imaging in Cancer | |
| McLarty | Molecular Imaging as a Tool for Predicting and Monitoring Response of Breast Cancer to Trastuzumab (Herceptin (R)) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |